ZMB Member Martin Schuler
ZMB Member
Martin Schuler
Next ZMB-Member
Prof. Dr. Martin Schuler
Director of:
Department of Medical Oncology
University Hospital Essen
Hufelandstraße 55
45147 Essen
- +49 201 723 2000
- Website
- Selected Publications
- Publication Metrics
- ZMB Research Program
Oncology
Research Overview
Clinical research
- Biomarker-stratified early clinical drug development
- Immuno-oncology
- Lung cancer and thoracic oncology
Translational and clinical-related basic research
- Mechanisms of drug resistance and immune evasion
- Mechanisms of tumor progression and metastasis
- Lung cancer biology
Selected Publications
-
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease : a secondary analysis from MARIPOSAIn: Annals of Oncology Vol. 35 (2024) Nr. 9, pp. 805 - 816Online Full Text: dx.doi.org/ (Open Access)
-
Evolutionary trajectories of small cell lung cancer under therapyIn: Nature Vol. 627 (2024) Nr. 8005, pp. 880 - 889Online Full Text: dx.doi.org/ (Open Access)
-
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR) : An international, single-arm, phase 2 studyIn: The Lancet Oncology Vol. 24 (2023) Nr. 8, pp. 925 - 935Online Full Text: dx.doi.org/
-
Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic CancerIn: The New England Journal of Medicine Vol. 388 (2023) Nr. 1, pp. 33 - 43Online Full Text: dx.doi.org/
-
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant MelanomaIn: Clinical Cancer Research Vol. 28 (2022) Nr. 14, pp. 3002 - 3010Online Full Text: dx.doi.org/ (Open Access)
-
Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With CancerIn: JAMA Oncology Vol. 8 (2022) Nr. 12, pp. 1830 - 1839Online Full Text: dx.doi.org/
-
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer EntitiesIn: Clinical Cancer Research Vol. 28 (2022) Nr. 19, pp. 4346 - 4353Online Full Text: dx.doi.org/ (Open Access)
-
Corrigendum to “Inhibiting fibroblast growth factor receptors in cancer – The next generation”In: Annals of Oncology Vol. 32 (2021) Nr. 1, pp. 126Online Full Text: dx.doi.org/ (Open Access)
-
FAST : a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinomaIn: Annals of Oncology Vol. 32 (2021) Nr. 5, pp. 609 - 619Online Full Text: dx.doi.org/ (Open Access)
-
Phase I assessment of safety and therapeutic activity of BAY1436032 in patients with IDH1-mutant solid tumorsIn: Clinical Cancer Research Vol. 27 (2021) Nr. 10, pp. 2723 - 2733Online Full Text: dx.doi.org/ (Open Access)
-
Sotorasib for Lung Cancers with KRAS p.G12C MutationIn: The New England Journal of Medicine Vol. 384 (2021) Nr. 25, pp. 2371 - 2381Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Crizotinib in ROS1 and MET deregulated NSCLC-letterIn: Clinical Cancer Research Vol. 26 (2020) Nr. 7, pp. 1774Online Full Text: dx.doi.org/ (Open Access)
-
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer : Clinical and biomarker results from a phase I trialIn: Annals of Oncology Vol. 31 (2020) Nr. 6, pp. 789 - 797Online Full Text: dx.doi.org/ (Open Access)
-
The quest for efficient trial designs in precision oncologyIn: The Lancet Oncology Vol. 21 (2020) Nr. 12, pp. 1539 - 1541Online Full Text: dx.doi.org/
-
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus : the MONO studyIn: Annals of Oncology Vol. 30 (2019) Nr. 9, pp. 1487 - 1495Online Full Text: dx.doi.org/ (Open Access)
-
Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer : A Phase 1b Clinical TrialIn: JAMA Oncology Vol. 5 (2019) Nr. 2, pp. e184475Online Full Text: dx.doi.org/ (Open Access)
-
Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small-cell lung cancerIn: Annals of Oncology Vol. 30 (2019) Nr. 4, pp. 655 - 657Online Full Text: dx.doi.org/ (Open Access)
-
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression : a phase 1 dose-escalation and dose-expansion studyIn: The Lancet Oncology Vol. 20 (2019) Nr. 10, pp. 1454 - 1466Online Full Text: dx.doi.org/
-
Health-related quality of life (HR-QoL) in elderly soft tissue sarcoma (STS) patients from the randomized phase II EPAZ study comparing pazopanib (PAZ) and doxorubicin (DOX) in first lineIn: Annals of Oncology Vol. 29 (2018) Nr. Suppl. 8, pp. viii577Online Full Text: dx.doi.org/ (Open Access)
-
A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors : Results from rogaratinib Phase-1 studyIn: Annals of Oncology Vol. 28 (2017) Nr. Suppl. 5,
-
Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer : Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO)In: Annals of Oncology Vol. 28 (2017) Nr. Suppl. 5,
-
First-line afatinib for advanced EGFRm1 NSCLC : Analysis of long-term responders (LTRs) in the LUX-Lung (LL) 3, 6 and 7 trialsIn: Annals of Oncology Vol. 28 (2017) Nr. Suppl. 2,
-
Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer : secondary analysis of a randomized trialIn: Annals of Oncology Vol. 28 (2017) Nr. 5, pp. 1084 - 1089Online Full Text: dx.doi.org/ (Open Access)
-
Inactivation of Capicua drives cancer metastasisIn: Nature Genetics Vol. 49 (2017) Nr. 1, pp. 87 - 96Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Spatiotemporally restricted arenavirus replication induces immune surveillance and type i interferon-dependent tumour regressionIn: Nature Communications Vol. 8 (2017) pp. 14447Online Full Text: dx.doi.org/ (Open Access)
-
Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC in LUX-Lung (LL) 3, 6 and 7In: Annals of Oncology Vol. 28 (2017) Nr. Suppl. 5,Online Full Text: dx.doi.org/
-
1236P - Global named patient use (NPU) program of afatinib, an oral ErbB family blocker, in heavily pretreated advanced non-small cell lung carcinoma (NSCLC) patients who progressed following prior therapies, including erlotinib or gefitinib (E/G)In: Annals of Oncology Vol. 27 (2016) Nr. Supplement 6, pp. vi427Online Full Text: dx.doi.org/
-
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1) : updated results from the multicentre, open-label, phase 1 trialIn: The Lancet Oncology Vol. 17 (2016) Nr. 4, pp. 452 - 463Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib : phase III randomized LUX-Lung 5 trialIn: Annals of Oncology Vol. 27 (2016) Nr. 3, pp. 417 - 423Online Full Text: dx.doi.org/ (Open Access)
-
Cetuximab biweekly (q2w) plus mFOLFOX6 as 1st line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC) – Primary endpoint and subgroup analysis of the CEBIFOX trialIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl.6, pp. 508POnline Full Text: dx.doi.org/
-
Combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC) : phase 2 resultsIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 2, pp. ii127 - ii128Online Full Text: dx.doi.org/
-
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma : post hoc analyses of the randomized LUX-Lung 3 and 6 trialsIn: Annals of Oncology Vol. 27 (2016) Nr. 11, pp. 2103 - 2110Online Full Text: dx.doi.org/ (Open Access)
-
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIOIn: The Lancet Oncology Vol. 17 (2016) Nr. 12, pp. 1697 - 1708Online Full Text: dx.doi.org/
-
IMAB362 : a novel immunotherapeutic antibody targeting the tight-junction protein component CLAUDIN18.2 in gastric cancerIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 2, pp. ii141 - ii142Online Full Text: dx.doi.org/
-
Reply to the letter to the editor ‘What is the clinical impact of the LUX-Lung 5 trial?’ by AddeoIn: Annals of Oncology Vol. 27 (2016) Nr. 6, pp. 1172 - 1173Online Full Text: dx.doi.org/
-
developmental therapeuticsPhase I study of the pan-fibroblast growth factor receptor (FGFR) inhibitor BAY 1163877 with expansion cohorts for subjects based on tumor FGFR mRNA expression levelsIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6, 360O_PROnline Full Text: dx.doi.org/
-
Afatinib (A) versus chemotherapy (CT) for EGFR mutation-positive NSCLC patients (pts) aged ≥65 years : Subgroup analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)In: Annals of Oncology Vol. 26 (2015) Nr. S 9: ESMO Asia Congress, 18-21 December 2015, Singapore : Submitted Abstracts, pp. 136 - 137
-
Afatinib (a) plus paclitaxel (p) following progression on a monotherapy in patients (pts) with metastatic non-small-cell lung cancer (nsclc) who previously benefited from erlotinib (e)/gefitinib (g) : a global randomised phase iii triallux-lung 5 (ll5)In: Annals of Oncology Vol. 26 (2015) Nr. S 1, pp. i33 - i34Online Full Text: dx.doi.org/
-
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6) : analysis of overall survival data from two randomised, phase 3 trialsIn: The Lancet Oncology Vol. 16 (2015) Nr. 2, pp. 141 - 151Online Full Text: dx.doi.org/
-
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations : A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6In: The Lancet Oncology Vol. 16 (2015) Nr. 7, pp. 830 - 838Online Full Text: dx.doi.org/
-
Comprehensive genomic profiles of small cell lung cancerIn: Nature Vol. 524 (2015) Nr. 7563, pp. 47 - 53Online Full Text: dx.doi.org/ (Open Access)
-
Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)In: Annals of Oncology Vol. 26 (2015) Nr. S 6, pp. vi73 - vi89Online Full Text: dx.doi.org/
-
Overall survival (OS) with afatinib (A) vs chemotherapy (CT) in patients (pts) with NSCLC harboring EGFR mutations (mut) : Subgroup analyses by race in LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)In: Annals of Oncology Vol. 26 (2015) Nr. S 9: ESMO Asia Congress, 18-21 December 2015, Singapore : Submitted Abstracts, pp. 136Online Full Text: dx.doi.org/
-
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer : Results from the European EURAF CohortIn: Annals of Oncology Vol. 26 (2015) Nr. S 1: European Lung Cancer Conference (ELCC), Geneva, Switzerland, 15-18 April 2015 : Abstracts, pp. i61Online Full Text: dx.doi.org/
-
Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutationsIn: The New England Journal of Medicine Vol. 373 (2015) Nr. 8, pp. 726 - 736Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Ceritinib in ALK-Rearranged Non–Small-Cell Lung CancerIn: The New England Journal of Medicine Vol. 370 (2014) Nr. 13, pp. 1189 - 1197Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations in Lux-Lung 3, a phase III trial of afatinib or cisplatin/pemetrexed EGFR mutation-positive lung cancerIn: Annals of Oncology Vol. 23 (2012) Nr. Suppl. 9, pp. 410 - 411
-
LUX-Lung 3 : Symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutationsIn: Annals of Oncology Vol. 23 (2012) Nr. Suppl. 9, pp. 402
-
Lux-LungG 3 : Afatinib versus cisplatin and pemetrexed in Japanese patients with adenocarcinoma of the lung harboring an EGFR mutationIn: Annals of Oncology Vol. 23 (2012) Nr. Suppl. 11, pp. 8
-
Phase IB dose-escalation study of BEZ235 or BKM 120 in combination with paclitaxel (PTX) in patients with advanced solid tumorsIn: Annals of Oncology Vol. 23 (2012) Nr. Suppl. 9, pp. 157 - 158
-
Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with epcampositive relapsed or refractory advanced-stage breast cancerIn: Annals of Oncology Vol. 23 (2012) Nr. 9, pp. 2306 - 2313Online Full Text: dx.doi.org/ (Open Access)
-
An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancerIn: Annals of Oncology Vol. 21 (2010) Nr. 2, pp. 275 - 282Online Full Text: dx.doi.org/
-
ERBB2 Induces an Antiapoptotic Expression Pattern of Bcl-2 Family Members in Node-Negative Breast CancerIn: Clinical Cancer Research Vol. 16 (2010) Nr. 2, pp. 451 - 460Online Full Text: dx.doi.org/